Navigation Links
Anterios, Inc., Announces Results of Consumer Survey Revealing Widespread Problem of Excessive Sweating and Desire for New Topical Botulinum Toxin Treatment

NEW YORK, Nov. 14, 2013 /PRNewswire/ -- Anterios, Inc., a privately held aesthetic medicine and medical dermatology biopharmaceutical company, announced today survey results showcasing the current consumer sentiment around excessive sweating and a new potential topical botulinum treatment option that the Company is developing for hyperhidrosis, the medically extreme form of excessive sweating. The survey found that 17% of men and women in the survey -- equating to approximately 50 million people in the United States -- indicate that their antiperspirants are ineffective and that they sweat too much. 3.2% of men and women in the survey -- equating to approximately 10 million people in the United States -- indicate that they suffer from hyperhidrosis as self-scored on the Hyperhidrosis Disease Severity Scale as "Moderate" or "Severe". The survey was conducted via the Internet, collecting a nationally randomized sample of 2,599 men and women respondents.  The goal of the survey was to assess how excessive sweating impacted consumers as well as to understand the interest in and willingness to pay for treatment with ANT-1207, a patented topical botulinum toxin type A treatment that is in clinical development.

This survey showed that 54% of women and 37% of men who said they "sweat too much" indicated that they are likely to go to a physician's office to seek evaluation and possible treatment with a new, potential in-office treatment for hyperhidrosis with a topical botulinum prescription lotion – ANT-1207 -- if it were to be available after FDA approval.  74% of women and 67% of men who scored themselves as "having hyperhidrosis" indicated that they are likely to go to a physician's office to seek evaluation and potential treatment with ANT-1207 if it were to be available.

"This survey demonstrates the sizable unmet clinical need regarding excessive sweating that ANT-1207 could potentially address for consumers. Meeting this need represents a material commercial opportunity," stated Jon Edelson, MD, CEO and Founder of Anterios.

In the survey, approximately 80% of women and 60% of men who scored themselves as having hyperhidrosis indicated that their condition made them anxious or worried. Among this group, about half of men and women indicated that they have avoided certain social situations (e.g., dates, dinners with friends) because of the condition and approximately one-quarter of this group indicated that the condition actually prevented them from being intimate. 40% of survey respondents report that their work was negatively impacted because of this condition. Respondents also ranked excessive sweating as their top personal issue, right after weight loss, but substantially beating out acne, wrinkles and thinning hair.

"The clinical trial results to date for ANT-1207 have been promising," states William P. Coleman, III, MD, clinical investigator and dermatologist in private practice, clinical professor at Tulane University, Health Sciences Center, Editor in Chief of Dermatologic Surgery and former President of the American Society for Dermatologic Surgery.  "As a clinician in practice and a researcher in the field of hyperhidrosis, I see how devastating hyperhidrosis can be to these patients, impacting their personal and professional lives every day. And there are many of these patients. The 3.2% incidence of hyperhidrosis that this study found replicates very closely what was found in large published epidemiologic studies. While injectable botulinum is a highly effective treatment for hyperhidrosis and is approved by the FDA, it requires 30 to 40 needlesticks, which are a substantial barrier to treatment for many patients. Having an effective topical botulinum treatment could be a game changer for both patients and their treating physicians. In clinical studies conducted to date, ANT-1207 shows clinical activity for 6 months from a single treatment, which would provide these patients with a significant window of relief."

  The survey demonstrated that the underarms were, by far, the top choice for body location sought by women and men consumers for treatment of their excessive sweating. If treatment with ANT-1207 were to be successful for the underarms, and then available for other treatment areas, 45% women would want treatment for their foreheads, followed by the groin (31%); 43% of men would want treatment for their groins, followed by the forehead (41%). The back, hands, and feet were also areas where both women and men would want additional treatments.

About ANT-1207
ANT-1207, Botulinum Toxin Type A, Topical Lotion, is an investigational product being developed for the potential treatment of facial wrinkles, hyperhidrosis (excessive sweating) and other FDA-approved clinical indications for injectable botulinum as well as new potential clinical indications such as acne. The company believes that this treatment has the potential to greatly expand the market for botulinum treatments as it would overcome the limitations of injection, which include pain, bleeding and bruising as well as the potential for needle misplacement.

ANT-1207 is a lotion that takes five to ten minutes to apply in the physician's office, where it is fully massaged into the skin. Unlike many botulinum-based products, ANT-1207 does not require reconstitution in the physician's office prior to use, making it convenient and time-saving for the physician and the physician's staff. ANT-1207 incorporates a highly purified botulinum developed from Anterios' proprietary cell line of C. botulinum, Type A.  

About Anterios, Inc.
Anterios, Inc. ("Anterios") is a privately held clinical stage biopharmaceutical company which is developing next generation botulinum-based prescription products for aesthetic medicine and dermatology. Anterios has developed a proprietary platform technology that enables local, targeted delivery of botulinum toxin and other macromolecules across the skin without needles or other invasive treatments that can be destructive to the skin. In the future, Anterios plans to develop additional dermatology products to topically deliver other active ingredients, as well as products for delivery by other modalities. More information can be found at

SOURCE Anterios, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
2. AquaLiv Technologies, Inc. and Its Subsidiary, AquaLiv, Inc., Release Funding Updates
3. Agility Clinical, Inc., a Specialty Contract Research Organization is Formed
4. Pinnaclife, Inc., Announces NDC, Inc., to Exclusively Distribute the New Animal Health Product Line!
5. Sanguine Appoints Darlene Rosario, Vice President of Regulatory Affairs & Quality at Biothera, Inc., to Clinical Advisory Board and Ethics Committee
6. Genomatica, Inc., Award-Winning Industrial Biotechnology Pioneer, Selects Alexandria Real Estate Equities, Inc. for Long-Term, Mission-Critical R&D Facility and Corporate Headquarters
7. Free Research Report on Dyax Corp., Ebix, Inc., 8x8, Inc., EnerSys and Express Scripts Holding Co.
8. A Look Inside, Factors of Health - Research Report on Novogen Limited, Sanofi SA, ISIS Pharmaceuticals, Inc., Amgen, Inc. and Gilead Sciences, Inc.
9. R&D, Innovation Key to Success - Research Report on Varian Medical Systems, Inc., Boston Scientific Corporation, Stryker Corporation, St. Jude Medical, Inc., and Thermo Fischer Scientific Inc.
10. Testing Positive for Stability & Growth - Research Report on CombiMatrix Corporation, Cepheid, PerkinElmer, Inc., Life Technologies Corp. and Laboratory Corp. of America Holdings
11. Alexandria Real Estate Equities, Inc. Announces Long-Term Lease with Leading Global Commercial-Stage Oncology Company, Onyx Pharmaceuticals, Inc., for New Build-to-Suit Facility in South San Francisco, California
Post Your Comments:
(Date:6/27/2016)... ... 27, 2016 , ... Cancer experts from Austria, Hungary, Switzerland, ... a new and helpful biomarker for malignant pleural mesothelioma. Surviving Mesothelioma has just ... now. , Biomarkers are components in the blood, tissue or body fluids ...
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers ... 5000 and the 6000i models are higher end machines that use the more unconventional ... spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci has ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
Breaking Biology Technology:
(Date:5/9/2016)... -- Elevay is currently known as the ... high net worth professionals seeking travel for work   ... there is still no substitute for a face-to-face meeting. ... deal with a firm handshake. This is why wealthy ... citizenship via investment programs like those offered by the ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
(Date:4/19/2016)... , UAE, April 20, 2016 ... be implemented as a compact web-based "all-in-one" system solution ... the biometric fingerprint reader or the door interface with ... of modern access control systems. The minimal dimensions of ... ID readers into the building installations offer considerable freedom ...
Breaking Biology News(10 mins):